Compound(3393-45-1)Application of 3393-45-1 received a lot of attention, and I have introduced some compounds in other articles, similar to this compound(5,6-Dihydro-2H-pyran-2-one), if you are interested, you can check out my other related articles.
Most of the compounds have physiologically active properties, and their biological properties are often attributed to the heteroatoms contained in their molecules, and most of these heteroatoms also appear in cyclic structures. A Journal, Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov’t, Journal of Pharmacology and Experimental Therapeutics called Novel antimuscarinic antidepressant-like compounds with reduced effects on cognition, Author is Johnson, Chad R.; Kangas, Brian D.; Jutkiewicz, Emily M.; Winger, Gail; Bergman, Jack; Coop, Andrew; Woods, James H., which mentions a compound: 3393-45-1, SMILESS is O=C1C=CCCO1, Molecular C5H6O2, Application of 3393-45-1.
The cholinergic nervous system was implicated in mood disorders, evident in the fast-onset antidepressant effects of scopolamine, a potent muscarinic antagonist, in clin. studies. One prominent disadvantage of the use of scopolamine in the treatment of depression was its detrimental effects on cognition, especially as such effects might aggravate cognitive deficits that occurred with depression itself. Thus, the identification of antimuscarinic drugs that were free of such detrimental effects might provide an important avenue for the development of novel therapeutics for the management of depression. The present data in rats indicated that a historical muscarinic antagonist I, and a muscarinic antagonist II, were as or more effective than scopolamine in antagonizing both the bradycardic effects of the muscarinic agonist arecoline in cardiovascular studies and its discriminative stimulus and rate-decreasing effects in behavioral studies. Addnl., both novel muscarinic antagonists I and II were as effective as scopolamine in decreasing immobility in the forced swim test, a preclin. indicator of potential antidepressant activity. However, at equieffective or even larger doses, they were considerably less disruptive than scopolamine in assays of cognition-related behavior. All three drugs displayed high specificity for the mAChRs with few off-target binding sites, and II showed modest affinity across the mAChRs when compared with I and scopolamine. These data emphasize the dissimilar pharmacol. profiles that were evident across antimuscarinic compounds and the potential utility of novel antagonists for the improved treatment of depression.
Compound(3393-45-1)Application of 3393-45-1 received a lot of attention, and I have introduced some compounds in other articles, similar to this compound(5,6-Dihydro-2H-pyran-2-one), if you are interested, you can check out my other related articles.
Reference:
Metal catalyst and ligand design,
Ligand Template Strategies for Catalyst Encapsulation – NCBI